X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Omya showcases multifunctional mineral excipients and active ingredients

Content Team by Content Team
21st September 2021
in News
Omya showcases multifunctional mineral excipients and active ingredients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

At CPhI Worldwide, mineral expert Omya will present its range of innovative mineral excipients for pharmaceutical and nutraceutical applications. In addition to the newly launched Omyanutra® 300 DC and Omyanutra® 300 Flash for nutraceutical tablets, the focus will also be on Omyapharm® – a porous mineral excipient that facilitates the production of tablets and granules with excellent compactability, high mechanical stability and fast disintegration. Visitors will be able to see various prototypes and experience the multiple benefits of Omya’s range.

Omyapharm® fine powder is an excellent filler-binder for tablets in dry granulation processes. It improves tablet compactability while significantly reducing disintegration time, thanks to the high porosity of the structured mineral. This results in harder tablets at low compression forces that quickly disintegrate.

Omya will also highlight the recently launched Omyanutra® 300 DC and Omyanutra® 300 Flash, which are made of high-purity, natural mineral material. Omyanutra® 300 DC is a directly compressible version of the company’s proprietary functionalised calcium carbonate excipient that comes as free-flowing granules and excellent tablet compactability. Omyanutra® 300 Flash comes with a superdisintegrant and is therefore a perfect all-in-one solution for manufacturers of orally and fast-disintegrating tablets.

In addition, the company will showcase its active pharmaceutical ingredients Omyapure® and Omya-Cal®. Both are valuable components for calcium supplementation, antacids and bone health applications.

Thus, Bone Boost is a chewable tablet concept containing Omyapure® as the active ingredient, as well as vitamins K2 and D3 from the company’s distribution portfolio. B12 Flash is an orally disintegrating tablet (ODT) based on the excipient Omyanutra® 300 Flash combined with vitamin B12, which helps to reduce tiredness and fatigue. The ActivFresh prototype contains mint oil loaded onto Omyanutra® 300 DC, that conveniently brings oil into tablet formulations while mataining good compactability, mechanical stability and disintegration time.

During CPhI 2021, the company’s team of pharma experts will be available to discuss further possible applications. With the combined use of its proprietary calcium minerals and specialty ingredients from its wide-ranging distribution portfolio, Omya is able to provide holistic solutions for various concepts that meet current market demands.

About Omya Group
Omya International AG is a leading global producer of calcium carbonates and a worldwide distributor of specialty additives, premium services, and solutions. Founded in 1884 in Switzerland, Omya has a global presence extending to more than 160 locations in over 50 countries with 9,000 employees. Omya provides sustainable added-value products and services from responsibly sourced materials to meet current and future generations' needs. Omya offers innovative solutions based on high purity natural minerals and complementary ingredients that comply with the most stringent regulatory and quality standards in the Consumer Goods sector.

Previous Post

Pureos Bioventures Expands the Team by the Appointment of Venture Partners

Next Post

Samsung Biologics showcases its newest CDO process platform, S-CellerateTM, at BPI 2021, offering expedited timeline to IND and BLA

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Samsung Biologics showcases its newest CDO process platform, S-CellerateTM, at BPI 2021, offering expedited timeline to IND and BLA

Samsung Biologics showcases its newest CDO process platform, S-CellerateTM, at BPI 2021, offering expedited timeline to IND and BLA

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In